NEUROONE MEDICAL TECHNOLOGIES Corp 8K

NeuroOne reported Q1 FY2026 results with guidance for at least $10.5 million in FY2026 product revenue, expanded adoption and regulatory progress for its OneRF ablation platform, ongoing pipeline and partnership developments, and a Q1 net loss of $1.4 million with funding expected through fiscal 2026.

On February 17, 2026, NeuroOne Medical Technologies Corporation reported its fiscal first quarter 2026 results and business update, highlighting expected fiscal 2026 product revenue of at least $10.5 million (at least 17% growth over 2025), recently obtained FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System and successful completion of nine facial pain cases, expanding adoption of its OneRF ablation platform, advancement of multiple pain and drug-delivery programs and related strategic partnership discussions, and financial metrics including Q1 FY26 product revenue of $2.9 million, a net loss of $1.4 million, cash and cash equivalents of $3.6 million, and the belief that it is funded through fiscal 2026, alongside the announcement of an investor conference call on the same date.

Filing Facts

CIK

1500198

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-016912

Alert Tier

7